Mainstay Medical‘s (MSTY.PA) European initial public offering reeled in about $25 million (€18 million) and made the spinal implant maker the 1st medtech company to float an IPO in Paris and the 1st company to attempt a dual flotation in Paris and Dublin, the Irish Times reports.
Wall Street Beat
Teleflex gains on strong Q1, Intuitive Surgical supply deal
Endo Health posts Q1 loss on $830M AMS mesh settlement
Endo Health Solutions (NSDQ:ENDP) said it struck an $830 million deal to settle thousands of lawsuits over its American Medical Systems pelvic mesh products.
Abiomed reveals HHS probe into provider payments
Weather-induced FDA delay hits Staar Surgical’s bottom line
California-based STAAR Surgical (NSDQ:STAA) swung hard to a 1st-quarter loss after storm-related regulatory delays cost the company its bottom line.
C.R. Bard posted major profit growth in its 1st quarter | Medtech Wall Street news for the week of Apr. 28, 2014
Did a Russian oligarch’s fall take down Biopure successor OPK Biotech?
Creditors hoping to collect $1.4 billion from OPK Biotech are seeking to force the Biopure Corp. successor into Chapter 7 bankruptcy.
Legal loss pushes NuVasive to Q1 red
NuVasive Inc. (NSDQ:NUVA) swung to a 1st-quarter loss after a jury ruled against it in a trademark infringement battle with NeuroVision, prompting the medical device company to lower its 2014 earnings outlook and investors to pare more than 2% from its share price.
CardioDx resurrects IPO dreams
More than 5 months after ditching efforts to open on public markets, California-based CardioDx is ready to take another swing at an initial public offering.
In regulatory documents filed this week the molecular diagnostics maker assigned new underwriters, named a couple of new executives and added 2 members to its board of directors. CardioDx has not yet revealed exact timing or terms for the revived IPO.